Proteomics & Protein Research

The company is currently in discussions with several investor groups and plans to use the funds to expand the reach of the test and prepare for FDA submission.

The method combines post-translational modification data and 3D protein structure data to identify known and novel biologically significant hotspots.

Named Helios, the new platform allows for better sampling efficiency and larger sample volumes as well as improved sensitivity and mulitplexing.

The arrangement will join Nuclea's expertise in proteomics with Aelan's genomics know-how.

Intended for diagnosing active pulmonary tuberculosis, the test will use Cere's Nanotrap reagents for enriching target analytes for downstream analysis.